Famitinib

Phase 2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gastrointestinal Stromal Tumor

Conditions

Gastrointestinal Stromal Tumor

Trial Timeline

Mar 1, 2012 → Jun 1, 2019

NCT ID

NCT02336724

About Famitinib

Famitinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Gastrointestinal Stromal Tumor. The current trial status is unknown. This product is registered under clinical trial identifier NCT02336724. Target conditions include Gastrointestinal Stromal Tumor.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05473468	Phase 1	UNKNOWN	Aug 26, 2022	Nov 1, 2022	Healthy Subjects
NCT04479904	Phase 2	Withdrawn	Aug 10, 2020	Feb 10, 2022	Intrahepatic Cholangiocarcinoma
NCT01762293	Phase 2	Completed	Apr 1, 2012	Oct 1, 2014	Colorectal Cancer
NCT02336724	Phase 2	UNKNOWN	Mar 1, 2012	Jun 1, 2019	Gastrointestinal Stromal Tumor
NCT01994213	Phase 2	Terminated	Oct 1, 2011	May 1, 2016	Gastroenteropancreatic Neuroendocrine Tumor
NCT01392235	Phase 2	Completed	Jul 1, 2011	Aug 1, 2016	Recurrent Nasopharyngeal Carcinoma

Competing Products

20 competing products in Gastrointestinal Stromal Tumor

See all competitors

Product	Company	Stage	Hype Score
Raludotatug Deruxtecan (R-DXd)	Daiichi Sankyo	Phase 2	52
Patritumab deruxtecan	Daiichi Sankyo	Phase 1/2	41
DS-6157a	Daiichi Sankyo	Phase 1	33
DS-8201a + Physician's Choice	Daiichi Sankyo	Phase 2	52
Naldemedine + Placebo	Shionogi	Phase 2	52
Gemcitabine	Eli Lilly	Phase 1/2	41
Olaratumab	Eli Lilly	Phase 2	52
pemetrexed + cisplatin	Eli Lilly	Phase 2	52
cetuximab	Eli Lilly	Phase 2	52
BBI503	Sumitomo Pharma	Phase 2	52
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + Regorafenib	Sumitomo Pharma	Phase 1/2	41
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)	Johnson & Johnson	Phase 3	77
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)	Johnson & Johnson	Phase 2	52
Remimazolam Tosilate	Jiangsu Hengrui Medicine	Approved	85
Famitinib capsules + Sunitinib Capsules	Jiangsu Hengrui Medicine	Phase 3	77
Esomeprazole IV + Omeprazole IV	AstraZeneca	Phase 3	77
Durvalumab + FLOT chemotherapy	AstraZeneca	Phase 3	77
Esomeprazole	AstraZeneca	Phase 3	77
AZD2171	AstraZeneca	Phase 2	52
Esomeprazole	AstraZeneca	Phase 3	77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved